A recent paper, linked here,
outlines the indications for screening and the reasons why. This has
been a bit controversial, since gene product replacement has been
supported only by clinical data on surrogate endpoints. However, the
article makes a compelling case for screening based on several
reasons. First, the surrogate based evidence is mounting. Second,
there are multiple reasons beyond product replacement to justify
screening.
No comments:
Post a Comment